期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 8, 期 2, 页码 211-223出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2010.0014
关键词
Prostate cancer; survivorship; GnRH agonists; osteoporosis; diabetes; obesity; coronary heart disease
类别
资金
- NCI NIH HHS [K24 CA121990, K24 CA121990-04, K24 CA121990-03] Funding Source: Medline
Androgen deprivation therapy (ADT) plays a central role in the management of men with locally advanced, recurrent, and metastatic prostate cancer. Because most men diagnosed with prostate cancer will die of something other than their cancer, treatment-related adverse effects are highly relevant to their long-term health. Benefits of ADT in each clinical setting must be weighed against ADT-related adverse effects. ADT is detrimental to several metabolic end points and to bone health. ADT has been prospectively shown to cause decreased lean muscle mass, increased fat mass, weight gain, increased cholesterol and triglycerides, insulin resistance, and loss of bone mineral density. In population-based analyses it has been associated with an increased incidence of diabetes, clinical fractures, and cardiovascular disease. Data-driven recommendations for managing these adverse effects are needed. Currently the authors advocate the use of adapted practice guidelines developed to prevent diabetes, fractures, and coronary heart disease in the general population. (JNCCN 2010;8:211-223)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据